Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)

• Main Authors: Alexander C. Razavi (Author), LaTonia C. Richardson (Author), Fátima Coronado (Author), Omar Dzaye (Author), Harpreet S. Bhatia (Author), Anurag Mehta (Author), Arshed A. Quyyumi (Author), Viola Vaccarino (Author), Matthew J. Budoff (Author), Khurram Nasir (Author), Sotirios Tsimikas (Author), Seamus P. Whelton (Author), Michael J. Blaha (Author), Roger S. Blumenthal (Author), Laurence S. Sperling (Author)
• Format: Book
• Published: Elsevier, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Lipoprotein(a) [Lp(a)] is an atherogenic and prothrombotic lipoprotein associated with atherosclerotic cardiovascular disease (ASCVD). We assessed the association between regular aspirin use and ASCVD mortality among individuals with versus without elevated Lp(a) in a nationally represent...